Literature DB >> 9848331

A non-randomized comparison of two radiotherapy protocols in inoperable squamous cell carcinoma of the oesophagus.

N R Datta1, S Kumar, S Nangia, S Hukku, S Ayyagari.   

Abstract

We report an audit of two different telebrachytherapy schedules in inoperable carcinoma of the oesophagus. Between October 1990 and December 1996, 108 patients with a Karnofsky performance status > or = 50 were selected from our database on the basis of intention to treat by telebrachytherapy. Teletherapy in the low dose group L (55 patients) consisted of 35 Gy in 15 fractions over 3 weeks, while that in the high dose group H (53 patients) consisted of 50 Gy in 25 fractions over 5 weeks. The choice of teletherapy dose was based on physician preference. The high dose rate intraluminal radiotherapy that followed 2 weeks later was identical in both groups and consisted of two applications of 6 Gy, a week apart. The pretreatment disease characteristics of the patients in both arms were similar. Relief of dysphagia was obtained in 49% of the patients in group L and in 75% of those in group H (chi2: P = 0.004). The median dysphagia-free interval was 0 and 7 months in groups L and H respectively (log-rank: P = 0.06), while the median overall survival was identical at 8 months (log-rank: P = 0.21) for both groups. The probability of survival at 1, 2 and 5 years was 34.8% versus 35.8%, 14.5% versus 13.9% and 0% versus 10% for groups L and H respectively. Morbidity in the form of ulcers, strictures and fistulae were observed in 9%, 7% and 5% of patients in group L compared with 8%, 8% and 13% in groups H respectively. This audit suggests that the protocol used in group H, when compared with group L, results in a greater proportion of patients being rendered dysphagia free, with a statistical trend towards a greater sustainment of dysphagia relief on follow-up.

Entities:  

Mesh:

Year:  1998        PMID: 9848331     DOI: 10.1016/s0936-6555(98)80083-6

Source DB:  PubMed          Journal:  Clin Oncol (R Coll Radiol)        ISSN: 0936-6555            Impact factor:   4.126


  2 in total

1.  Palliative radiotherapy in esophageal cancer.

Authors:  N R Vishnu Prasad; M Karthigeyan; Kate Vikram; R Parthasarathy; K S Reddy
Journal:  Indian J Surg       Date:  2013-01-26       Impact factor: 0.656

2.  High dose rate brachytherapy (HDR-BT) in locally advanced oesophageal cancer. Clinic response and survival related to biological equivalent dose (BED).

Authors:  Maria C López Carrizosa; P Maria Samper Ots; A Rodríguez Pérez; A Sotoca; J Sáez Garrido; M M de Miguel
Journal:  Clin Transl Oncol       Date:  2007-06       Impact factor: 3.340

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.